Literature DB >> 22366188

Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer.

Bertram E Yuh1, Nora H Ruel, Rosa Mejia, Chelsea M Wilson, Timothy G Wilson.   

Abstract

BACKGROUND: Accurate staging of prostate cancer is enhanced by a thorough evaluation of the pelvic lymph nodes. Limited data are available regarding robotic extended pelvic lymphadenectomy (PLA) in this setting.
OBJECTIVE: Analyze our experience performing robotic extended PLA. DESIGN, SETTING, AND PARTICIPANTS: A total of 143 consecutive men with intermediate- or high-risk clinically localized adenocarcinoma of the prostate underwent robotic extended PLA and radical prostatectomy between September 2010 and November 2011 by a single surgeon. SURGICAL PROCEDURE: Lymph node packets were sent separately from bilateral common, external, and internal iliacs, obturators, node of Cloquet, and anterior prostatic fat. MEASUREMENTS: Descriptive statistics were used to summarize lymph node yields and positive nodes. Clinical variables were examined in logistic regression models to predict lymph node positivity. RESULTS AND LIMITATIONS: Median lymph node yield was 20 (range: 9-65, interquartile range: 15-25). Eighteen patients (13%) were found to have metastatic prostate cancer in the lymph nodes. The mean number of positive nodes found was 2.9 (range: 1-11). In 14 of 18 node-positive patients (78%), the extent of nodal invasion was outside the boundaries of a limited PLA. For four patients with positive nodes (22%), prostate biopsy predicted unilateral disease but PLA revealed contralateral positive lymph nodes. A total of 82% of patients experienced no complications, and most Clavien grade 1-2 complications consisted of anastomotic leakage, urinary retention, ileus, and lymphocele. Only 4% of patients experienced a grade 3 complication. Under multivariate regression analysis, prostate-specific antigen (PSA), clinical stage, and maximum biopsy core tumor volume were identified as significant predictors of finding positive pelvic lymph nodes (area under the curve: 91%). The main limitations include short follow-up and lack of randomization.
CONCLUSIONS: Robotic extended bilateral PLA for prostate cancer up to the common iliac bifurcation increases nodal yield and positive nodal rate and can be performed safely. PSA, clinical stage, and maximum biopsy core volume are predictors for lymph node invasion. Long-term follow-up is needed to evaluate for therapeutic benefit.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22366188     DOI: 10.1016/j.eururo.2012.01.048

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  18 in total

1.  Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy.

Authors:  Anup Kumar; Srinivas Samavedi; Anthony S Bates; Vladimir Mouraviev; Rafael F Coelho; Bernardo Rocco; Vipul R Patel
Journal:  J Robot Surg       Date:  2016-07-19

2.  Body mass index is an independent predictor of Clavien-Dindo grade 3 complications in patients undergoing robot assisted radical prostatectomy with extensive pelvic lymph node dissection.

Authors:  Antonio Benito Porcaro; Marco Sebben; Alessandro Tafuri; Nicolò de Luyk; Paolo Corsi; Tania Processali; Marco Pirozzi; Riccardo Rizzetto; Nelia Amigoni; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Giovanni Novella; Vincenzo De Marco; Filippo Migliorini; Walter Artibani
Journal:  J Robot Surg       Date:  2018-05-08

3.  Preclinical evaluation of robotic-assisted sentinel lymph node fluorescence imaging.

Authors:  Michael A Liss; Salman Farshchi-Heydari; Zhengtao Qin; Sean A Hickey; David J Hall; Christopher J Kane; David R Vera
Journal:  J Nucl Med       Date:  2014-07-14       Impact factor: 10.057

Review 4.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

5.  Clinical and oncological outcomes of robot-assisted radical prostatectomy with nerve sparing vs. non-nerve sparing for high-risk prostate cancer cases.

Authors:  Kiyoshi Takahara; Makoto Sumitomo; Kosuke Fukaya; Takahito Jyoudai; Masashi Nishino; Masaru Hikichi; Kenji Zennami; Takuhisa Nukaya; Manabu Ichino; Naohiko Fukami; Hitomi Sasaki; Mamoru Kusaka; Ryoichi Shiroki
Journal:  Oncol Lett       Date:  2019-07-31       Impact factor: 2.967

6.  Robotic-assisted fluorescence sentinel lymph node mapping using multimodal image guidance in an animal model.

Authors:  Michael A Liss; Sean P Stroup; Zhengtao Qin; Carl K Hoh; David J Hall; David R Vera; Christopher J Kane
Journal:  Urology       Date:  2014-08-16       Impact factor: 2.649

7.  Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy.

Authors:  Avinash Chenam; Jaspreet S Parihar; Nora Ruel; Sumanta Pal; Yvonne Avila; Jonathan Yamzon; Clayton Lau; Bertram Yuh
Journal:  J Robot Surg       Date:  2017-09-13

8.  Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy.

Authors:  Michael A Liss; Kerrin Palazzi; Sean P Stroup; Ramzi Jabaji; Omer A Raheem; Christopher J Kane
Journal:  World J Urol       Date:  2013-03-20       Impact factor: 4.226

9.  Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer.

Authors:  Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Paolo Corsi; Tania Processali; Marco Pirozzi; Davide De Marchi; Davide Inverardi; Maria A Cerruto; Nelia Amigoni; Riccardo Rizzetto; Matteo Brunelli; Roberto Iacovelli; Salvatore Siracusano; Walter Artibani
Journal:  Curr Urol       Date:  2019-07-20

10.  Managing urine leakage following laparoscopic radical prostatectomy with active suction of the prevesical space.

Authors:  Milan Hora; Petr Stránský; Jiří Klečka; Ivan Trávníček; Tomáš Urge; Viktor Eret; Jiří Ferda; Fredrik Petersson; Ondřej Hes
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2012-10-30       Impact factor: 1.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.